Samuel Armstrong Lane's first successful treatment of haemophilia with blood transfusion in 1840: Could this also be the first successful bypassing therapy?

Poon, Man‐Chiu; Card, Robert T.

doi:10.1111/hae.13645

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concurrently, early developments in immunology led to the use of sera raised in animals against the microorganisms responsible for diphtheria and tetanus in the treatment and pathogenesis of the diseases [ 2 ]. Blood and plasma transfusion was also used as an early treatment of haemophilia [ 3 , 4 ]. All these early treatments, covering most of the spectrum of current plasma protein therapeutics, were derived from single or small pools of individual donors of blood or plasma, generally in a hospital setting and very distant from a pharmaceutical manufacturing environment.…”

Section: Background—the Development Of Plasma-derived Pharmaceuticalsmentioning

confidence: 99%

The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative

Farrugia

2023

Pathogens

View full text Add to dashboard Cite

Chronic recipients of plasma products are at risk of infection from blood-borne pathogens as a result of their inevitable exposure to agents which will contaminate a plasma manufacturing pool made up of thousands of individual donations. The generation of such a pool is an essential part of the large-scale manufacture of these products and is required for good manufacturing practice (GMP). Early observations of the transmission of hepatitis by pooled plasma and serum led to the incorporation of heat treatment of the albumin solution produced by industrial Cohn fractionation of plasma. This led to an absence of pathogen transmission by albumin over decades, during which hepatitis continued to be transmitted by other early plasma fractions, as well as through mainstream blood transfusions. This risk was decreased greatly over the 1960s as an understanding of the epidemiology and viral aetiology of transfusion-transmitted hepatitis led to the exclusion of high-risk groups from the donor population and the development of a blood screening test for hepatitis B. Despite these measures, the first plasma concentrates to treat haemophilia transmitted hepatitis B and other, poorly understood, forms of parenterally transmitted hepatitis. These risks were considered to be acceptable given the life-saving nature of the haemophilia treatment products. The emergence of the human immunodeficiency virus (HIV) as a transfusion-transmitted infection in the early 1980s shifted the focus of attention to this virus, which proved to be vulnerable to a number of inactivation methods introduced during manufacture. Further developments in the field obviated the risk of hepatitis C virus (HCV) which had also infected chronic recipients of plasma products, including haemophilia patients and immunodeficient patients receiving immunoglobulin. The convergence of appropriate donor selection driven by knowledge of viral epidemiology, the development of blood screening now based on molecular diagnostics, and the incorporation of viral inactivation techniques in the manufacturing process are now recognised as constituting a “safety tripod” of measures contributing to safety from pathogen transmission. Of these three components, viral inactivation during manufacture is the major contributor and has proven to be the bulwark securing the safety of plasma derivatives over the past thirty years. Concurrently, the safety of banked blood and components continues to depend on donor selection and screening, in the absence of universally adopted pathogen reduction technology. This has resulted in an inversion in the relative safety of the products of blood banking compared to plasma products. Overall, the experience gained in the past decades has resulted in an absence of pathogen transmission from the current generation of plasma derivatives, but maintaining vigilance, and the surveillance of the emergence of infectious agents, is vital to ensure the continued efficacy of the measures in place and the development of further interventions aimed at obviating safety threats.

show abstract

Section: Background—the Development Of Plasma-derived Pharmaceuticalsmentioning

confidence: 99%

The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative

Farrugia

2023

Pathogens

View full text Add to dashboard Cite

show abstract

“…Леонард Ландуа продемонстрировал вместе с Альбертом Эйленбургом (1840-1917), немецким психиатром и фармакологом, эффективность применения переливания крови у собак, отравленных угарным газом, хлороформом, эфиром, стрихнином, морфином и фосфором. Вебер и Блазиус предприняли попытку переливания крови в случае лейкемии, к сожалению, безуспешную (Maluf 1954 (Farr 1981;Poon, Card 2019).…”

Section: переливание крови при заболеванияхunclassified

Blood transfusion: The genesis

Никитина¹

2022

IPh

View full text Add to dashboard Cite

Аннотация. XIX век -время становления переливания крови, история которого уходит вглубь веков. В этот период после полуторавекового забвения вновь возрождается интерес к гемотрансфузии, в чем ключевую роль сыграл Эдинбургский университет, именно с его выпускниками связано становление переливания крови. Среди них прежде всего необходимо выделить Джеймса Бланделла, осуществившего в 1818 г. первое переливание от человека к человеку. Работы Бланделла представляли одно из первых систематических исследований в области переливания крови и положили начало новой эре трансфузионной медицины. Им и его последователями, многие из которых незаслуженно забыты, была доказана опасность гетерологичного переливания крови; выявлено, что венозная кровь так же подходит для переливания, как и артериальная; разработаны подходы к предотвращению свертывания крови, в том числе подогревание, дефибринирование и использование антикоагулянтов; усовершенствованы методические приемы, применяемые при трансфузиях инструменты и устройства; отмечено, что в них не должен попадать воздух. Одновременно с развитием гемотрансфузии проводились исследования внутривенного введения различных жидкостей и газов, способствовавшие развитию внутривенной терапии. Однако переливание крови внедрялось в медицинскую практику довольно медленно, так как нередко приводило к гибели пациентов. Это было обусловлено как несовершенством процедуры и инструментария, так и непознанностью причин несовместимости человеческой крови. Данный обзор отражает основные направления развития переливания крови в XIX веке в зарубежной физиологии и медицине.

show abstract

Samuel Armstrong Lane's first successful treatment of haemophilia with blood transfusion in 1840: Could this also be the first successful bypassing therapy?

Cited by 2 publications

References 12 publications

The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative

The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative

Blood transfusion: The genesis

Contact Info

Product

Resources

About